Literature DB >> 15824910

Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy.

Mirko Di Martino1, Luca Degli Esposti, Pierfrancesco Ruffo, Silvia Bustacchini, Alessandro Catte, Alessandra Sturani, Ezio Degli Esposti.   

Abstract

BACKGROUND: Many studies have indicated the adequate use of lipid-lowering drugs (LLDs) as a factor in reducing the risk of cardiovascular disease. However, in clinical practice, a very high percentage of patients are not adequately treated.
OBJECTIVE: To analyze the management of hypercholesterolemia in a non-experimental setting and to estimate the factors associated with poor adherence to treatment.
METHODS: A longitudinal study was performed using clinical and demographic data recorded in the General Practitioners' database. The sample included all patients, aged 30 years or over, with total blood cholesterol measured between 1 January and 31 December 2000. Utilization of LLDs was defined as the standardized daily dose of the drugs purchased during the 12 months preceding the cholesterol measurement.
RESULTS: The study included 4764 patients (mean age 59.4+/-14.1 years, 40.7% males). Of the subjects with a total cholesterol higher than a 6.5 mmol/l, approximately 17% were treated with LLDs. About 39% of the patients with previous atherosclerotic diseases were taking statins. Analysis of patients taking LLDs showed that 40.6% of subjects took less than half of the defined daily dose. Factors associated with poor adherence to treatment were: absence of previous atherosclerotic diseases, absence of concomitant diseases, and smoking. A total cholesterol of less than 5 mmol/l was achieved in 19.9% of patients.
CONCLUSIONS: Analyzing the data contained in the general medicine database made it possible to evaluate the use of LLDs in clinical practice and to establish the need to pay greater attention to achieving the objective set by the treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824910     DOI: 10.1007/s00228-005-0911-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

Review 1.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

2.  Variations and increase in use of statins across Europe: data from administrative databases.

Authors:  Tom Walley; Pietro Folino-Gallo; Ulrich Schwabe; Eric van Ganse
Journal:  BMJ       Date:  2004-02-14

3.  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.

Authors: 
Journal:  Eur Heart J       Date:  1997-10       Impact factor: 29.983

4.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

Review 5.  Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

Authors:  S E Andrade; A M Walker; L K Gottlieb; N K Hollenberg; M A Testa; G M Saperia; R Platt
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

6.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

7.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

8.  Use and monitoring of "statin" lipid-lowering drugs compared with guidelines.

Authors:  S A Abookire; A S Karson; J Fiskio; D W Bates
Journal:  Arch Intern Med       Date:  2001-01-08

9.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

View more
  8 in total

1.  Early discontinuation: more frequent among general practitioners with high levels of prescribing.

Authors:  Dorte Gilså Hansen; Anthony Gichangi; Werner Vach; Lina Hoel Felde; John Larsen
Journal:  Eur J Clin Pharmacol       Date:  2007-07-06       Impact factor: 2.953

2.  Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage.

Authors:  Elisabetta Poluzzi; Petar Strahinja; Alberto Vaccheri; Antonio Vargiu; Maria Chiara Silvani; Domenico Motola; Giulio Marchesini; Fabrizio De Ponti; Nicola Montanaro
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

Review 3.  Atorvastatin: pharmacological characteristics and lipid-lowering effects.

Authors:  Andrea Poli
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities.

Authors:  Heli Halava; Maarit Jaana Korhonen; Risto Huupponen; Soko Setoguchi; Jaana Pentti; Mika Kivimäki; Jussi Vahtera
Journal:  CMAJ       Date:  2014-06-23       Impact factor: 8.262

5.  Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.

Authors:  Nele Laleman; Séverine Henrard; Marjan van den Akker; Geert Goderis; Frank Buntinx; Gijs Van Pottelbergh; Bert Vaes
Journal:  BMC Cardiovasc Disord       Date:  2018-11-06       Impact factor: 2.298

Review 6.  Determinants of Non-Adherence to the Medications for Dyslipidemia: A Systematic Review.

Authors:  João Lopes; Paulo Santos
Journal:  Patient Prefer Adherence       Date:  2021-08-24       Impact factor: 2.711

7.  GPs' Perceptions of Cardiovascular Risk and Views on Patient Compliance: A Qualitative Interview Study.

Authors:  Benedicte Lind Barfoed; Dorte Ejg Jarbøl; Maja Skov Paulsen; Palle Mark Christensen; Peder Andreas Halvorsen; Jesper Bo Nielsen; Jens Søndergaard
Journal:  Int J Family Med       Date:  2015-10-08

8.  Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis.

Authors:  Heidemarie Keller; Oliver Hirsch; Petra Kaufmann-Kolle; Tanja Krones; Annette Becker; Andreas C Sönnichsen; Erika Baum; Norbert Donner-Banzhoff
Journal:  BMC Public Health       Date:  2013-07-02       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.